After a relatively quiet IPO market, 2019 has emerged as the year of the digital health IPO with Health Catalyst, Livongo Health, Phreesia, and Change Healthcare all going public earlier this year and Peloton going public in October. Will this last?
Rock Health calculated there was $29.4 billion in capital invested in digital health startups since 2011 that were still waiting on returns and examined the two routes companies have to return liquidity to investors: IPOs and M&A.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Beginning in June, the Livongo for Diabetes program will be available to Medicare Advantage members of Cambia Health Solutions' regional health plans.
Livongo has revealed a new voice-enabled blood pressure monitoring system, which is powered by Amazon Lex and Amazon Polly.
The myStrength news comes fresh off the heels of competitor Omada Health's effort to add on similar services using technology developed by failed behavioral health startup Lantern.
The company has signed a perpetual licencing deal for the software, curriculum and content of Lantern, which built digital therapeutics for mental health conditions before shutting down operations last year.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Mountain View, California-based Livongo Health, founded in 2014 by former Allscripts CEO Glen Tullman, has raised around $240 million in venture funding.
The Series E round, which was led by existing investors General Catalyst and Kinnevik, included participation from Merck Global Health Innovation Fund, Microsoft Ventures and others.
https://www.youtube.com/watch?v=wDq1-jOzVyA Livongo Health, a company launched last year by Glen Tullman, a former CEO of Allscripts, has raised $20 million in a Series B round, according to an emailed statement from Tullman. The fresh capital will be used to support the young company’s development of its FDA-cleared blood glucose monitoring device and digital diabetes management […]